Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $16.59 USD
Change Today -0.33 / -1.95%
Volume 3.1M
BSX On Other Exchanges
New York
As of 11:58 AM 02/11/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 Boston Scientific Way

Marlborough, MA 01752

United States

Phone: 508-683-4000


Boston Scientific Corporation operates as a developer, manufacturer, and marketer of medical devices that are used in a range of interventional medical specialties worldwide. Products During 2014, the company’s products were offered for sale by seven core businesses, such as Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Women’s Health, Neuromodulation, and Electrophysiology. Cardiovascular Interventional Cardiology Drug-Eluting Coronary Stent Systems The company markets a portfolio of internally-developed and self-manufactured drug-eluting stents, including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, the company markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. The SYNERGY Stent is unique in that both its proprietary polymer and everolimus drug coating dissipate by three months. Core Coronary Technology The company markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease, which is characterized by a thickening of the walls of the coronary arteries and a narrowing of arterial openings caused by the progressive development of deposits of plaque. The company’s product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty procedures. Intravascular Imaging The company markets a family of intravascular catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The company’s new Intravascular Ultrasound Imaging catheter, OptiCross has been launched in all major markets worldwide. The iLab Ultrasound Imaging System continues as the company’s primary console and is compatible with its line of imaging catheters, and its new Polaris software, designed to run on the iLab System, has been approved in Japan, the United States (U.S.), and Europe; and is launching in select markets. The iLab System is designed to improve the diagnosis and treatment of blocked vessels and heart disorders. Further, these systems have been placed in cardiology labs worldwide, which provide an installed base through which the company expects to launch new products, including an integrated Fractional Flow Reserve device. Structural Heart Therapy The company owns Sadra Medical, Inc. (Sadra). Through the acquisition of Sadra, the company has developed a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The company also owns Atritech, Inc. (Atritech). Atritech developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. Peripheral Interventions The company sells various products designed to treat patients with peripheral disease (disease, which appears in blood vessels other than in the heart and in the biliary tree), including a line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. The company’s peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters. The company’s peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon; its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures; and its Charger PTA Balloon Catheter, a 0.035 inch PTA balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. With the company’s Coyote, Mustang, and Charger devices, it offers balloons across all size platforms. The company’s periphe


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $16.59 USD -0.33

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $35.98 USD -0.93
Olympus Corp ¥4,065 JPY -25.00
Smith & Nephew PLC 1,051 GBp -30.00
St Jude Medical Inc $49.56 USD -1.16
Zimmer Biomet Holdings Inc $91.55 USD -1.36
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.6x
Price/Cash Flow 88.6x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at